1. Home
  2. INKT vs ENLV Comparison

INKT vs ENLV Comparison

Compare INKT & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MiNK Therapeutics Inc.

INKT

MiNK Therapeutics Inc.

HOLD

Current Price

$8.60

Market Cap

53.7M

Sector

Health Care

ML Signal

HOLD

Logo Enlivex Therapeutics Ltd.

ENLV

Enlivex Therapeutics Ltd.

SELL

Current Price

$1.11

Market Cap

4.0M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
INKT
ENLV
Founded
2017
2005
Country
United States
Israel
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
53.7M
4.0M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
INKT
ENLV
Price
$8.60
$1.11
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
★ $44.00
N/A
AVG Volume (30 Days)
11.9K
★ 95.1K
Earning Date
11-11-2026
12-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.48
$0.16
52 Week High
$15.27
$7.64

Technical Indicators

Market Signals
Indicator
INKT
ENLV
Relative Strength Index (RSI) 30.86 49.47
Support Level N/A $1.02
Resistance Level $11.92 $1.26
Average True Range (ATR) 0.69 0.12
MACD -0.15 -0.05
Stochastic Oscillator 9.38 20.54

Price Performance

Historical Comparison
INKT
ENLV

About INKT MiNK Therapeutics Inc.

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.

About ENLV Enlivex Therapeutics Ltd.

Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.

Share on Social Networks: